Adding interferon-alpha to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours.
Division of Hepatology and Gastroenterology & Interdisciplinary, Centre of Endocrinology and Metabolism, Department of Internal Medicine, Charité, Campus Virchow Klinikum, Berlin, Germany.
Ulrich Frank
UF
Pape
Bertram
B
Wiedenmann